ABBV · News · 20260923N
Licensing / Collaboration Deals
AbbVie Inc. · 2026-09-23 · Importance 46 · Surprise 42 · In source text
AbbVie entered a multi-year research collaboration with Iambic Therapeutics, an AI drug-discovery company backed by Nvidia and Qatar Investment Authority. The collaboration gives AbbVie access to Iambic’s AI platform for designing drug candidates in immunology, neuroscience, and oncology. AbbVie will make a $40 million upfront payment and could pay up to $670 million in milestone payments, making the arrangement financially material under the stated threshold.
Key facts
- AbbVie announced a multi-year research collaboration with Iambic Therapeutics that involves an upfront payment of $40 million and potential milestone payments of up to $670 million. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| liability | negative | contingent | -0.0% | AbbVie announced a multi-year research collaboration with Iambic Therapeutics that involves an upfront payment of $40 million and… |
| cash | negative | committed | -0.0% | AbbVie announced a multi-year research collaboration with Iambic Therapeutics that involves an upfront payment of $40 million and… |